Navigation Links
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Date:11/13/2008

08 should be disclosed in the next few months."

CONSOLIDATED RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2008

Consolidated sales and royalties increased to $8.6 million for the three-month period ended September 30, 2008, compared to $7.4 million for the same period in 2007. The increase in sales and royalties for the three-month period ended September 30, 2008 compared to the same period last year is related primarily to additional sales of Cetrotide(R), partly offset by the exclusion of sales from Impavido(R) in the third quarter of 2008.

License fees revenues decreased to $2.4 million for the three-month period ended September 30, 2008 compared to $3.7 million for the same period in 2007. The decrease for the three-month period ended September 30, 2008, compared to the same period in 2007, is mainly attributable to a milestone payment received in 2007 from Ardana plc.

Consolidated R&D costs, net of tax credits and grants were $13.9 million for the three-month period ended September 30, 2008 compared to $9.8 million for the same period in 2007. Additional R&D expenses for the three-month period ended September 30, 2008, compared to the same period in 2007 are mainly related to the advancement of the Phase 3 program in BPH with the compound, cetrorelix.

Consolidated selling, general and administrative (SG&A) expenses were $3.3 million for the three-month period ended September 30, 2008 compared to $5.8 million for the same period in 2007. The decrease in SG&A expenses for the three-month period ended September 30, 2008 compared to the same period in 2007 is primarily related to organizational changes and cost saving measures that were implemented in the second quarter of 2008.

Consolidated net loss for the three-month period ended September 30, 2008 was $13.9 million or $0.26 per basic and diluted share compared to $8.7 million or $0.16 per basic and diluted share for the same period in 2007. The increase in net loss
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
2. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
4. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
10. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
11. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Tenn. , May 4, 2015   ... developed a significantly better computer tool for finding ... many cancers but were difficult to identify with ... scientific journal Nature Methods . ... for Copy Number Segmentation by Regression Tree in ...
(Date:5/4/2015)... /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio ... Dr. Roger J Garceau, to its Board of ... matters including corporate development and clinical strategy, his ... regulatory expertise as Fluorinov transitions to clinical development.  ... of pharmaceutical development experience to Fluorinov and most ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain additive, ... better detail than the industry standard. But because ... methods, it needed another medium to measure its detail. ... reference because it represents the highest standard of detail ... discovery days of Ultralight Histology was to reverse engineer ...
(Date:5/4/2015)... --  Tocagen Inc. , a clinical-stage immuno-oncology company, ... investigational studies were presented at the 11 th ... Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section ... Washington, D.C. In addition, Tocagen ... and continues to advance towards initiation of a ...
Breaking Biology Technology:Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5
... ... enhance greenhouse gas reduction on the local level , , ... Marlborough, MA (PRWEB) October 24, 2009 -- Over forty employees at ... International Day of Climate Action , October 24, 2009. Climate Change awareness actions such as ...
... - Dr. Brad Thompson, President and CEO of Oncolytics ... present a corporate overview of the Company at the ... 28, 2009 at 3:00 p.m. PT. The conference will ... on October 28 and 29, 2009. , A live ...
... YORK, Oct. 23 Pulmo BioTech Inc. (OTC ... that it will ultimately receive at least $3.3 ... the previously announced non-binding letter of intent with ... its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development ...
Cached Biology Technology:Qteros Employees Planting Special Trees in Celebration of International Day of Climate Action, October 24, 2009 2Qteros Employees Planting Special Trees in Celebration of International Day of Climate Action, October 24, 2009 3Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009 2Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 2Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 3Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 4
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... trackway with 12 consecutive prints provides the most compelling ... trackway, located in La Virgen del Campo track site ... continuous record of swimming by a non-avian therapod dinosaur. ... Patrimonio Paleontológico de La Rioja, La Rioja, Spain, discovered ...
... new gene therapy can nearly eliminate arthritis pain, and ... to a study published today in the journal Arthritis ... they are the first genetically engineered to develop osteoarthritis ... some more likely to develop the disease, the authors ...
... of Central and South America conduct spectacular predatory raids containing ... bodies to plug potholes in the trail leading back to ... be delivered to the developing young at maximum speed. , ... trail of forager traffic, along which prey-laden foragers run back ...
Cached Biology News:Definitive evidence found of a swimming dinosaur 2Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 2Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 3Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 4Ants show us how to make super-highways 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Preparation Note: Prepared by a modification ... et al., Biotechnol. Bioeng., ... One unit will yield an A ... ml of water (1 cm light ...
... Cleland’s Reagent, Immobilized White solid. PACKAGED ... of DTT on polyacrylamide resin with applications similar ... 233153 , 233156 , and 233155 ... soluble components are added to the system. REDUCTACRYL™ ...
... The Yeast Whole Genome ChIP-on-chip Microarray ... of yeast (S. cerevisiae) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
Biology Products: